FirstWord

Front-line sacituzumab tirumotecan plus Keytruda significantly boosted progression-free survival in patients with PD-L1 tumour proportion score <1%.

HUYABIO's HBI-8000 plus Bristol Myers Squibb's Opdivo achieved median progression-free survival of 11.7 months compared to 7.4 months for Opdivo plus placebo.

One analyst said detailed data from the CELIA study of Alzheimer's disease candidate diranersen "leave more questions than answers."

Chai Discovery has secured AI-powered drug discovery partnerships with Novartis, Pfizer and Eli Lilly.

The neuropsychiatry biotech builds on last year's $140 million launch as Phase II studies of its lead depression drug DT-101 continue.

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in...

7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculatureNew non-human primate data demon...

FirstWord spoke with Columbia University's Benjamin Herzberg about top-line Phase III Krascendo 1 results for Roche's divarasib, and how it and rival next-gen KRAS G12C inhibitors could could change NSCLC.

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial SettingTOKYO and CAMBRIDGE, Mas...

New presentations and expert-led scientific discussions underscore Kedrion's commitment to improving diagnosis, supporting disease awareness, and scientific exchange in rare diseasesFORT LEE, N.J., Ju...